Munich, Germany

Shinji Maegata

This inventor holds 1 USPTO granted patent. Top assignee: Bayer Aktiengesellschaft. Active years: 1990.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shinji Maegata. Retrieved from https://idiyas.com/inventor/shinji-maegata-5pcvmocb

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 75(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Shinji Maegata

Introduction

Shinji Maegata, an accomplished inventor based in Oharanaka, DE, has made significant strides in the pharmaceutical industry. With a focus on creating effective medication forms, his contributions have the potential to benefit countless patients.

Latest Patents

Maegata holds a patent for his invention titled "Press Coated DHP Tablets." This innovation pertains to solid pharmaceutical preparations with a long-lasting action, specifically for dihydropyridines in the form of press-coated tablets. This invention not only offers a new approach to medication delivery but also enhances the efficacy and patient compliance for long-term treatments.

Career Highlights

Currently employed at Bayer Aktiengesellschaft, Maegata is part of a renowned organization recognized worldwide for its research and development in pharmaceuticals. Throughout his career, he has focused on inventive approaches that address key challenges in medication formulation.

Collaborations

In the course of his work, Shinji Maegata has collaborated with esteemed colleagues such as Andreas Ohm and Helmut Luchtenberg. Their combined expertise fosters an environment of innovation that drives forward-thinking solutions in the field of pharmaceuticals.

Conclusion

Shinji Maegata's dedication to innovation in pharmaceutical preparations through his patented work exemplifies the impact inventors can have on healthcare. As he continues to contribute to Bayer Aktiengesellschaft and collaborate with talented professionals, his work promises to shape the future of medical treatments for patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…